Expression of vascular endothelial growth factor in malignant mesothelioma

Keisuke Aoe, Akio Hiraki, Takehiro Tanaka, Ken Ichi Gemba, Koji Taguchi, Tomoyuki Murakami, Naoko Sueoka, Toshiaki Kamei, Hiroshi Ueoka, Kazuro Sugi, Tadashi Yoshino, Takumi Kishimoto

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Malignant mesothelioma is the most common primary pleural neoplasm. Angiogenesis is an important component of a variety of pathological processes, including carcinogenesis and tumor metastases. Vascular endothelial growth factor (VEGF) is the most potent known endothelial, cell specific mitogen. The authors assessed the relation between VEGF expression and clinicopathological variables or overall survival, in malignant mesothelioma. We studied 37 patients with malignant pleural mesothelioma and found that 36 out of 37 (97.3%) malignant mesothelioma samples were stained positively for VEGF. An increased expression of VEGF was observed in the epithelioid type compared with the other histological types of malignant mesothelioma, including the biphasic and sarcomatoid types. No statistically significant association was observed between VEGF expression and gender, age, or clinical stage. Furthermore, the expression of VEGF did not impact on the survival of patients with malignant mesothelioma. Although VEGF expression might be important for tumor development and maintenance, it was not identified as a prognostic factor in malignant mesothelioma.

Original languageEnglish
Pages (from-to)4833-4836
Number of pages4
JournalAnticancer Research
Volume26
Issue number6 C
Publication statusPublished - Nov 2006

Fingerprint

Vascular Endothelial Growth Factor A
Pleural Neoplasms
Survival
Pathologic Processes
Malignant Mesothelioma
Mitogens
Neoplasms
Carcinogenesis
Endothelial Cells
Maintenance
Neoplasm Metastasis

Keywords

  • Immune escape mechanism
  • Malignant mesothelioma
  • Prognostic factor
  • VEGF

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Aoe, K., Hiraki, A., Tanaka, T., Gemba, K. I., Taguchi, K., Murakami, T., ... Kishimoto, T. (2006). Expression of vascular endothelial growth factor in malignant mesothelioma. Anticancer Research, 26(6 C), 4833-4836.

Expression of vascular endothelial growth factor in malignant mesothelioma. / Aoe, Keisuke; Hiraki, Akio; Tanaka, Takehiro; Gemba, Ken Ichi; Taguchi, Koji; Murakami, Tomoyuki; Sueoka, Naoko; Kamei, Toshiaki; Ueoka, Hiroshi; Sugi, Kazuro; Yoshino, Tadashi; Kishimoto, Takumi.

In: Anticancer Research, Vol. 26, No. 6 C, 11.2006, p. 4833-4836.

Research output: Contribution to journalArticle

Aoe, K, Hiraki, A, Tanaka, T, Gemba, KI, Taguchi, K, Murakami, T, Sueoka, N, Kamei, T, Ueoka, H, Sugi, K, Yoshino, T & Kishimoto, T 2006, 'Expression of vascular endothelial growth factor in malignant mesothelioma', Anticancer Research, vol. 26, no. 6 C, pp. 4833-4836.
Aoe K, Hiraki A, Tanaka T, Gemba KI, Taguchi K, Murakami T et al. Expression of vascular endothelial growth factor in malignant mesothelioma. Anticancer Research. 2006 Nov;26(6 C):4833-4836.
Aoe, Keisuke ; Hiraki, Akio ; Tanaka, Takehiro ; Gemba, Ken Ichi ; Taguchi, Koji ; Murakami, Tomoyuki ; Sueoka, Naoko ; Kamei, Toshiaki ; Ueoka, Hiroshi ; Sugi, Kazuro ; Yoshino, Tadashi ; Kishimoto, Takumi. / Expression of vascular endothelial growth factor in malignant mesothelioma. In: Anticancer Research. 2006 ; Vol. 26, No. 6 C. pp. 4833-4836.
@article{2531cf6312bd4af2be06d54607c4308d,
title = "Expression of vascular endothelial growth factor in malignant mesothelioma",
abstract = "Malignant mesothelioma is the most common primary pleural neoplasm. Angiogenesis is an important component of a variety of pathological processes, including carcinogenesis and tumor metastases. Vascular endothelial growth factor (VEGF) is the most potent known endothelial, cell specific mitogen. The authors assessed the relation between VEGF expression and clinicopathological variables or overall survival, in malignant mesothelioma. We studied 37 patients with malignant pleural mesothelioma and found that 36 out of 37 (97.3{\%}) malignant mesothelioma samples were stained positively for VEGF. An increased expression of VEGF was observed in the epithelioid type compared with the other histological types of malignant mesothelioma, including the biphasic and sarcomatoid types. No statistically significant association was observed between VEGF expression and gender, age, or clinical stage. Furthermore, the expression of VEGF did not impact on the survival of patients with malignant mesothelioma. Although VEGF expression might be important for tumor development and maintenance, it was not identified as a prognostic factor in malignant mesothelioma.",
keywords = "Immune escape mechanism, Malignant mesothelioma, Prognostic factor, VEGF",
author = "Keisuke Aoe and Akio Hiraki and Takehiro Tanaka and Gemba, {Ken Ichi} and Koji Taguchi and Tomoyuki Murakami and Naoko Sueoka and Toshiaki Kamei and Hiroshi Ueoka and Kazuro Sugi and Tadashi Yoshino and Takumi Kishimoto",
year = "2006",
month = "11",
language = "English",
volume = "26",
pages = "4833--4836",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 C",

}

TY - JOUR

T1 - Expression of vascular endothelial growth factor in malignant mesothelioma

AU - Aoe, Keisuke

AU - Hiraki, Akio

AU - Tanaka, Takehiro

AU - Gemba, Ken Ichi

AU - Taguchi, Koji

AU - Murakami, Tomoyuki

AU - Sueoka, Naoko

AU - Kamei, Toshiaki

AU - Ueoka, Hiroshi

AU - Sugi, Kazuro

AU - Yoshino, Tadashi

AU - Kishimoto, Takumi

PY - 2006/11

Y1 - 2006/11

N2 - Malignant mesothelioma is the most common primary pleural neoplasm. Angiogenesis is an important component of a variety of pathological processes, including carcinogenesis and tumor metastases. Vascular endothelial growth factor (VEGF) is the most potent known endothelial, cell specific mitogen. The authors assessed the relation between VEGF expression and clinicopathological variables or overall survival, in malignant mesothelioma. We studied 37 patients with malignant pleural mesothelioma and found that 36 out of 37 (97.3%) malignant mesothelioma samples were stained positively for VEGF. An increased expression of VEGF was observed in the epithelioid type compared with the other histological types of malignant mesothelioma, including the biphasic and sarcomatoid types. No statistically significant association was observed between VEGF expression and gender, age, or clinical stage. Furthermore, the expression of VEGF did not impact on the survival of patients with malignant mesothelioma. Although VEGF expression might be important for tumor development and maintenance, it was not identified as a prognostic factor in malignant mesothelioma.

AB - Malignant mesothelioma is the most common primary pleural neoplasm. Angiogenesis is an important component of a variety of pathological processes, including carcinogenesis and tumor metastases. Vascular endothelial growth factor (VEGF) is the most potent known endothelial, cell specific mitogen. The authors assessed the relation between VEGF expression and clinicopathological variables or overall survival, in malignant mesothelioma. We studied 37 patients with malignant pleural mesothelioma and found that 36 out of 37 (97.3%) malignant mesothelioma samples were stained positively for VEGF. An increased expression of VEGF was observed in the epithelioid type compared with the other histological types of malignant mesothelioma, including the biphasic and sarcomatoid types. No statistically significant association was observed between VEGF expression and gender, age, or clinical stage. Furthermore, the expression of VEGF did not impact on the survival of patients with malignant mesothelioma. Although VEGF expression might be important for tumor development and maintenance, it was not identified as a prognostic factor in malignant mesothelioma.

KW - Immune escape mechanism

KW - Malignant mesothelioma

KW - Prognostic factor

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=33845924511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845924511&partnerID=8YFLogxK

M3 - Article

VL - 26

SP - 4833

EP - 4836

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 C

ER -